GOLD COVID-19 guidance.

Global Initiative for Chronic Obstructive Lung Disease (GOLD).

Reducing chronic obstructive pulmonary disease hospital readmissions. An official American Thoracic Society workshop report.

Press VG, et al. Ann Am Thorac Soc. 2019;16(2):161-170.

Predicting acute exacerbations in chronic obstructive pulmonary disease.

Samp JC, et al. J Manag Care Spec Pharm. 2018;24(3):265-279.

Triple versus dual inhaler therapy in moderate‐to‐severe COPD: a systematic review and meta‐analysis of randomized controlled trials.

Zayed Y, et al. Clin Respir J. 2019;13(7):413-428.

Once-daily single-inhaler triple versus dual therapy in patients with COPD.

Lipson DA, et al. N Engl J Med. 2018; 378(18):1671-1680.

The effect of exacerbation history on outcomes in the IMPACT trial.

Halpin DMG, et al. Eur Respir J. 2020;55(5):1901921.

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicenter, phase 3 randomised controlled trial.

Ferguson GT, et al. Lancet Respir Med. 2018; 6(10):747-758.

Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD.

Rabe KF, et al. N Engl J Med. 2020;383(1):35-48.

Bringing stability to the chronic obstructive pulmonary disease patient: clinical and pharmacological considerations for frequent exacerbators.

Gulati S, Wells JM. Drugs. 2017;77(6):651-670.

Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.

Puhan MA, et al. Cochrane Database Syst Rev. 2016;12:CD005305.

Cinical Practice Tools and Resources

The COPD Foundation Pocket Consultant Guide Mobile App

The COPD Pocket Guide, provided by the COPD Foundation, contains comprehensive management information as well as resource tools. It can be downloaded onto any mobile device.

Modified Medical Research Council (mMRC) Dyspnea Scale

The mMRC scale, provided by MDCalc, allows for the baseline stratification of dyspnea in COPD, as well as other respiratory diseases.

COPD Assessment Test (CAT)

The CAT, provided by the American Academy of Family Physicians, allows assessment of the global impact of COPD (cough, sputum, dyspnea, chest tightness) on patient health status.

COPD Action Plan

The COPD Action Plan, provided by the American Lung Association, is a tool that facilitates the prevention, timely identification, and early and appropriate treatment of COPD exacerbations.

Patient Resources and Advocacy Organizations

The COPD Foundation Pocket Consultant Guide Patient-Focused Mobile App

The COPD Pocket Guide for Patients was designed to improve disease management and communication with a patient’s health care team. It includes patient resources such as inhaler and exercise videos as well as tools such as the wallet card and daily symptom tracker that help collect and share information with the health care team. It can be downloaded onto any mobile device.

American Lung Association

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.

COPD Foundation

The COPD Foundation’s mission is to prevent and cure COPD and to improve the lives of all people affected by COPD.

Global Initiative for Chronic Obstructive Lung Disease (GOLD)

GOLD partners with health care professionals and public health officials to raise awareness of COPD and to improve prevention and treatment of this lung disease for patients around the world.

National Jewish Health

National Jewish Health integrates the latest scientific discoveries with coordinated care for lung, heart, and immune diseases. Their Patient Education Program provides many free educational opportunities and support groups to assist patients and caregivers with managing illnesses and chronic conditions, such as COPD.